Written and maintained by CASRAI Editorial Board
Last updated
Short answer
Lipinski’s Rule of Five (Ro5) is a medicinal chemistry heuristic predicting whether a small molecule will have poor oral absorption and membrane permeability. Formulated by Christopher A. Lipinski in 1997, it flags compounds with more than 5 hydrogen bond donors, 10 hydrogen bond acceptors, molecular weight above 500 Da, or calculated LogP exceeding 5.
Definition and scope
Formulated in 1997 by Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy, and Paul J. Feeney at Pfizer Central Research (republished in 2001 in Advanced Drug Delivery Reviews), the Rule of Five evaluates whether a compound has the physical-chemical profile for oral bioavailability in humans.
The guideline was derived from an empirical analysis of 2,245 compounds in the World Drug Index (WDI) that had reached Phase II clinical trials, marked by USAN or INN designations. Phase II compounds were selected because entry into human efficacy trials demonstrates proven biological availability, filtering out insoluble screening artifacts.
The rule states that poor oral absorption or membrane permeation is likely when a molecule violates two or more of four thresholds:
- Molecular weight (MWT): Greater than 500 Da. Larger molecules diffuse slower across lipid bilayers.
- Lipophilicity (CLogP): Calculated partition coefficient greater than 5.0 (or Moriguchi MLogP > 4.15). Excessive lipophilicity traps compounds in bilayers and raises clearance.
- Hydrogen bond donors (HBD): More than 5 donors (sum of OH and NH groups). Donors impose high desolvation energy penalties.
- Hydrogen bond acceptors (HBA): More than 10 acceptors (sum of N and O atoms). Acceptors create bulky hydration shells.
The name “Rule of Five” refers to cutoffs being multiples of 5 (500 Da, LogP 5, 5 donors, 10 acceptors). It governs passive transcellular permeability, excluding active transport substrates, biologics, or non-oral routes.
How it works or how it is used in practice
In drug discovery, the Rule of Five serves as an in silico gating filter during virtual screening and hit-to-lead chemistry rather than a rigid release standard.
Discovery programs use computational pipelines to calculate 2D descriptors from connection tables and SMILES strings, flagging predicted violations automatically within cheminformatics filtering workflows. This prevents labs from synthesizing or purchasing unpromising chemical space.
During lead optimization, medicinal chemists face “molecular obesity”—the tendency of compounds to accumulate aromatic rings and molecular weight to boost target affinity. To manage this trade-off, teams classify compounds into violation tiers:
- Zero violations: Favorable oral druglikeness. Leads proceed to biological assays.
- One violation: Acceptable lead series. Roughly 16% of approved oral drugs violate one parameter. Teams retain these but track property inflation.
- Two or more violations: High failure risk. Passive membrane permeation drops sharply. Teams deprioritize the series unless active transport is established.
Computational Ro5 scores are validated experimentally. Labs assess turbidimetric solubility in microplate screens, test membrane transport via the Caco-2 cell permeability assay, and verify lipophilicity by measuring the octanol-water partition coefficient LogP.
Types or related concepts
Subsequent research expanded Lipinski’s framework to address molecular flexibility, fragment screening, and non-classical targets. The table below compares the primary property rules used in medicinal chemistry.
| Framework | Authors and Year | Cutoffs | Application | Key Limitation |
|---|---|---|---|---|
| Lipinski Rule of 5 (Ro5) | Lipinski et al. (1997, 2001) | MWT ≤ 500 Da; CLogP ≤ 5; HBD ≤ 5; HBA ≤ 10; flagged if ≥2 violations. | Small-molecule oral bioavailability filtering. | Passive permeability only; excludes active transport and macrocycles. |
| Veber’s Rules | Veber et al. (2002) | Rotatable bonds (NROT) ≤ 10; Polar surface area (tPSA) ≤ 140 Ų (or HBD + HBA ≤ 12). | Oral bioavailability in rats and humans. | Focuses on flexibility and polar area rather than molecular weight alone. |
| Rule of Three (Ro3) | Congreve et al. (2003) | MWT ≤ 300 Da; CLogP ≤ 3; HBD ≤ 3; HBA ≤ 3; NROT ≤ 3; tPSA ≤ 60 Ų. | Fragment-based lead discovery (FBDD). | Weak initial affinity; requires structural elaboration (“growing”). |
| Beyond the Rule of 5 (bRo5) | Doak et al. (2014) | MWT > 500 Da; intramolecular H-bonding. | Difficult targets: PPIs, PROTACs, viral proteases. | Requires conformational shielding; higher clearance risk. |
Veber’s rules (2002), based on pharmacokinetic data from over 1,100 drug candidates at SmithKline Beecham, showed that molecular weight ≤ 500 does not alone distinguish bioavailable compounds. Instead, molecular flexibility (rotatable bonds ≤ 10) and low polar surface area (tPSA ≤ 140 Ų) govern oral bioavailability. Profiling tools like SwissADME bioavailability tools evaluate Lipinski and Veber descriptors concurrently.
Congreve’s Rule of Three (2003) defines fragment libraries. Starting with MWT ≤ 300 and CLogP ≤ 3 ensures that optimized molecules remain inside Lipinski’s boundaries after structural growth.
Where it matters for labs, clinics or supply decisions
The Rule of Five directly guides screening library procurement, bench automation, and formulation budgets across research facilities.
When purchasing commercial compound libraries, lab managers use Ro5 compliance as a baseline specification. Procuring libraries with high molecular weight or extreme lipophilicity creates bench bottlenecks: compounds precipitate in DMSO stocks, clog liquid-handling tips, and produce optical artifacts in microplates.
In computational biology, applying Ro5 filters prior to structure-based molecular docking removes millions of impermeable decoys, conserving high-performance cluster computing time.
In translational projects, Ro5 compliance informs formulation decisions. Hits violating two or more Ro5 rules require complex formulation technologies—such as lipid nanoparticles or cyclodextrins—to achieve systemic exposure, increasing supply costs and timelines.
Common misunderstandings
Several frequent misunderstandings surround Lipinski’s Rule of Five:
- Misunderstanding: A single violation disqualifies a compound.
Reality: Lipinski defined poor permeability as violating two or more rules. Roughly 16% of approved oral drugs violate one rule (e.g., atorvastatin, MWT 558 Da). - Misunderstanding: The Rule of Five predicts biological potency.
Reality: The Ro5 measures solely physical-chemical solubility and passive permeability. It provides no information on target affinity, selectivity, or toxicity. - Misunderstanding: Passing the Rule of Five guarantees oral bioavailability.
Reality: Ro5 compliance is a necessary baseline for passive absorption, not a guarantee. Rapid hepatic clearance or P-glycoprotein efflux can eliminate systemic bioavailability for compliant molecules. - Misunderstanding: The number 5 denotes five distinct rules.
Reality: There are four parameters. The name stems from cutoff values: 500 Da, LogP 5, 5 donors, and 2 × 5 = 10 acceptors. - Misunderstanding: Natural products and macrocycles must obey the Rule of Five.
Reality: Many oral natural products (such as cyclosporine A, MWT 1,202 Da) violate Ro5 limits. They achieve bioavailability through “chameleonic” conformations, shielding polar groups in membranes and exposing them in aqueous solution.
Frequently asked questions
What is the difference between Lipinski’s Rule of 5 and Veber’s rules?
Lipinski’s Rule of 5 evaluates molecular weight (≤ 500 Da), lipophilicity (CLogP ≤ 5), hydrogen bond donors (≤ 5), and acceptors (≤ 10). Veber’s rules evaluate molecular flexibility via rotatable bond count (≤ 10) and polar surface area (tPSA ≤ 140 Ų). Veber demonstrated that rigid molecules with low polar area achieve oral bioavailability even when molecular weight exceeds 500 Da.
Why do natural products frequently violate Lipinski’s Rule of Five?
Natural products and cyclic peptides have evolved dynamic 3D conformations. In membrane interiors, they fold to form internal hydrogen bonds, hiding polar groups and facilitating passive permeability. In water, they unfold to expose polar groups. Many also utilize active transport systems that bypass passive diffusion constraints.
What is the difference between “lead-likeness” and “drug-likeness”?
Drug-likeness (Lipinski Ro5) characterizes approved oral drugs (MWT ≤ 500, LogP ≤ 5). Lead-likeness sets tighter limits (MWT ≤ 350, LogP ≤ 3) for screening hits. Beginning with a lead near Ro5 thresholds produces an optimized candidate that exceeds drug-like space after affinity optimization.
Sources
- Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1–3), 3–26. DOI: 10.1016/s0169-409x(00)00129-0. PMID: 11259830. [Read: 2026-11-09].
- Veber, D. F., Johnson, S. R., Cheng, H. Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615–2623. DOI: 10.1021/jm020017n. PMID: 12036371. [Read: 2026-11-09].
- Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003). A ‘rule of three’ for fragment-based lead discovery? Drug Discovery Today, 8(19), 876–877. DOI: 10.1016/s1359-6446(03)02831-9. PMID: 14554012. [Read: 2026-11-09].
- Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014). Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chemistry & Biology, 21(9), 1115–1142. DOI: 10.1016/j.chembiol.2014.08.013. PMID: 25237858. [Read: 2026-11-09].
